<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>SRx Health Solutions Redeems Series A Preferred Stock and Cancels Approximately 125,000,000 Shares of Common Stock, Improving Balance Sheet Flexibility for Investment in M&A or Return of Capital to Shareholders</title>
<style>
body { font-family: Arial, Helvetica, sans-serif; background:#0f1115; color:#e6e6e6; margin:0; padding:40px; }
.container { max-width:700px; margin:auto; background:#161a21; border-radius:10px; padding:32px; box-shadow:0 0 30px rgba(0,0,0,0.4); }
h1 { margin-top:0; color:#4da3ff; }
table { width:100%; margin-top:12px; border-collapse:collapse; }
th, td { text-align:left; padding:6px 8px; border-bottom:1px solid #2a2f3a; }
ul { margin-top:12px; padding-left:20px; }
.section { margin-top:24px; }
.small { margin-top:12px; font-size:13px; color:#999; }
a { color:#4da3ff; }
</style>
</head>
<body>
  <div class="container">
    <h1>SRx Health Solutions Redeems Series A Preferred Stock and Cancels Approximately 125,000,000 Shares of Common Stock, Improving Balance Sheet Flexibility for Investment in M&A or Return of Capital to Shareholders</h1>

    <table>
      <tr><th>Ticker</th><td>SRXH</td></tr>
      <tr><th>Float</th><td>42.0 M</td></tr>
      <tr><th>IO</th><td>0.81%</td></tr>
      <tr><th>MC</th><td>11.0 M</td></tr>
      <tr><th>Extra Info</th><td>None</td></tr>
    </table>

    <div class="section">
      <strong>Summary</strong>
      <p>SRx Health Solutions announced the redemption of 17,500 shares of its Series A Preferred Stock, which represents approximately 125,000,000 shares of common stock on an as-converted basis. The Series A was issued in a private placement on October 31, 2025 (19,035 shares for aggregate proceeds of ~$15.23 million). Management says the retirement of the preferred and cancellation of the as-converted common shares improves capital structure flexibility for future investments or potential return of capital. The company expects to file its Form 10-Q for the quarter ended December 31, 2025 on February 13, 2026 and noted it has no immediate undisclosed M&A plans. The release includes customary forward-looking statements and associated risks.</p>
    </div>

    <div class="section">
      <strong>Positives</strong>
      <ul><li>Redeemed Series A Preferred Stock, removing preferred position</li><li>Cancellation of ~125,000,000 as-converted common shares reduces potential dilution</li><li>Company states this improves capital structure flexibility for future investment or return of capital</li></ul>
    </div>

    <div class="section">
      <strong>Negatives</strong>
      <ul><li>No immediate, undisclosed M&A opportunities announced</li><li>Forward-looking statements subject to risks and uncertainties</li><li>Recent prior issuance (Oct 31, 2025) indicates recent dilution event that was later reversed for the as-converted shares</li></ul>
    </div>

    <div class="section">
      <a href="https://news.nuntiobot.com/article/febc9245-79e2-4186-8176-d5afb54a7428" target="_blank">Original Article</a>
    </div>

    <div class="small">SRXH â€¢ TradersLink AI News</div>
  </div>
</body>
</html>